Phaseline

Targets › CD200

CD200 (OX-2 membrane glycoprotein): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Dec 2032.

Costimulates T-cell proliferation. May regulate myeloid cell activity in a variety of tissues. (UniProt, P41217)

Open in Phaseline: the race on CD200, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Beat AML, LLCSamalizumab (BAML-16)
OX-2 membrane glycoprotein inhibitor
CD200Phase 2Previously Untreated Relapsed Refractory Acute Myeloid LeukemiaDec 2032

Conditions

Previously Untreated Relapsed Refractory Acute Myeloid Leukemia (1)

Modalities

mixed (1)

Companies

Beat AML, LLC (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.